These findings elucidate a mechanism through which TIGIT checkpoint inhibitors modify immunosuppressive tumor microenvironments and underscore the importance of FcγR engagement in developing anti-TIGIT antibodies (Guan et al., 2024b). The gene discussed is FCGR2A; the disease is neoplasm.